NCT02587195View on ClinicalTrials.gov

A Study to Evaluate the Safety of Long Term Treatment With Teriflunomide 14 mg Once Daily in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis in a Long-term Extension Period

PHASE3CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

December 18, 2015

Primary Completion Date

August 31, 2020

Study Completion Date

August 31, 2021

Conditions
Multiple Sclerosis
Interventions
DRUG

Teriflunomide

Trial Locations (5)

25030

CHU de Besançon, Besançon

34295

CHU de Montpellier, Montpellier

59037

CHU de Lille, Lille

67098

CHU de Strasbourg, Strasbourg

06000

CHU de Nice, Nice

All Listed Sponsors
lead

Centre Hospitalier Universitaire de Nice

OTHER

NCT02587195 - A Study to Evaluate the Safety of Long Term Treatment With Teriflunomide 14 mg Once Daily in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis in a Long-term Extension Period | Biotech Hunter | Biotech Hunter